Find Reports

Select Report Type

Reimbursement Review

Displaying 651 - 675 of 1258

Please scroll or swipe to the right to view the full content.

Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
Avastin	Bevacizumab	pcodr_provfund_avastin-oc.pdf pcodr_bevacizumab_avastin_oc-fn_rec.pdf pcodr_bevacizumab_avastin_oc-fn_cgr.pdf pcodr_bevacizumab_avastin_oc-fn_egr.pdf pcodr_bevacizumab_avastin_oc_in_rec.pdf pcodr_bevacizumab_avastin_oc_pagfdk.pdf pcodr_bevacizumab_avastin_oc_fdk_hlroche.pdf pcodr_bevacizumab_avastin_oc_ptfdk_occ.pdf pcodr_bevacizumab_avastin_oc_coi_occ_0.pdf	Ovarian Cancer	Reimburse with clinical criteria and/or conditions	Complete	Nov 28, 2014	Jun 4, 2015	PC0047-000
Istodax	Romidepsin	pcodr_provfund_istodax_ptcl.pdf pcodr_romidepsin_istodax_ptcl_fn_rec.pdf pcodr_romidepsin_istodax_ptcl_fn_cgr.pdf pcodr_romidepsin_istodax_ptcl_fn_egr.pdf pcodr_romidepsin_istodax_ptcl_in_rec.pdf pcodr_romidepsin_istodax_ptcl_pagfdk.pdf pcodr_romidepsin_istodax_ptcl_fdk_celgene.pdf	Peripheral T-Cell Lymphoma	Reimburse with clinical criteria and/or conditions	Complete	Dec 1, 2014	May 19, 2015	PC0048-000
Eylea	Aflibercept	cdr_SR0396_Eylea_DME.pdf SR0396_EyleaDME_CL_Report.pdf SR0396_EyleaDME_PE_Report.pdf cdr_complete_SR0396_Eylea-DME_May-11-15.pdf SR0396 Eylea DME_PI_Submissions.pdf	Macular edema, diabetic	List with clinical criteria and/or conditions	Complete	Sep 16, 2014	May 7, 2015	SR0396-000
Eylea	Aflibercept	cdr_SR0401_Eylea_CRVO.pdf cdr_complete_SR0401_Eylea-CRVO_May-11-15.pdf SR0401_EyleaCRVO_CL_Report.pdf SR0401_EyleaCRVO_PE_Report.pdf SR0401_EyleaCRVO_PI_Submissions.pdf	Macular edema, central retinal vein occlusion	List with clinical criteria and/or conditions	Complete	Oct 17, 2014	May 7, 2015	SR0401-000
Eliquis	Apixaban	cdr_SR0397_Eliquis_VTE.pdf cdr_complete_SR0397_Eliquis-VTE_May-11-15.pdf SR0397_EliquisVTE_CL_Report.pdf SR0397_EliquisVTE_PE_Report.pdf SR0397_Eliquis_VTE_PI_Submissions.pdf	Venous thromboembolic events, treatment and prevention of recurrence	List with clinical criteria and/or conditions	Complete	Sep 18, 2014	May 7, 2015	SR0397-000
Xolair	Omalizumab	cdr_SR0398_Xolair_CIU.pdf cdr_complete_SR0398_Xolair-CIU_May-11-15.pdf SR0398_XolairCIU_CL_Report.pdf SR0398_XolairCIU_PE_Report.pdf SR0398 Xolair_Template_PI_Submissions.pdf	Chronic idiopathic urticaria	List with clinical criteria and/or conditions	Complete	Sep 22, 2014	May 7, 2015	SR0398-000
Bosulif	Bosutinib	pcodr_profund_boustinib_bosulif_cml.pdf pcodr_bosutinib_bosulif_cml_fn_rec.pdf pcodr_bosutinib_bosulif_cml_fn_cgr.pdf pcodr_bosutinib_bosulif_cml_fn_egr.pdf pcodr_bosutinib_bosulif_cml_in_rec.pdf pcodr_bosutinib_bosulif_cml_pagfdk.pdf pcodr_bosutinib_bosulif_cml_fdk_pfizer.pdf pcodr_bosutinib_bosulif_cml_coi_cmlsc.pdf	Chronic Myeloid Leukemia	Reimburse with clinical criteria and/or conditions	Complete	May 30, 2014	Apr 21, 2015	PC0039-000
Xeljanz	Tofacitinib	cdr_SR0380_Xeljanz.pdf cdr_complete_SR0380_Xeljanz_Apr-21-15.pdf SR0380_Xeljanz_CL_Report.pdf SR0380_Xeljanz_PE_Report.pdf	Arthritis, rheumatoid	List with criteria/condition	Complete	May 5, 2014	Apr 17, 2015	SR0380-000
Cimzia	Certolizumab pegol	cdr_SR0385_Cimzia.pdf cdr_complete_SR0385_Cimzia-AS_Apr-21-15.pdf SR0385_Cimzia_AS_PI_Submissions.pdf SR0385_CimziaAS_CL_Report_e.pdf SR0385_CimziaAS_PE_Report_e.pdf	Ankylosing spondylitis	List with criteria/condition	Complete	Jun 23, 2014	Apr 17, 2015	SR0385-000
Juxtapid	Lomitapide	cdr_SR0386_Juxtapid.pdf cdr_complete_SR0386_Juxtapid-Apr-21_15.pdf SR0386_Juxtapid_CL_Report_e.pdf SR0386_Juxtapid_PE_Report_e.pdf media:document:1613e67a-34b5-425b-91a2-3240102d189c	Hypercholesterolemia, homozygous familial	Do not list	Complete	Jul 8, 2014	Apr 17, 2015	SR0386-000
Cimzia	Certolizumab pegol	SR0394 Cimzia PsA.PDF cdr_complete_SR0394_Cimzia-PsA_Apr-21-15.pdf SR0394_CimziaPsA_CL_Report.pdf SR0394_CimziaPsA_PE_Report.pdf SR0394 Cimzia PsA_PI_Submissions.pdf	Arthritis, psoriatic	List with criteria/condition	Complete	Sep 2, 2014	Apr 17, 2015	SR0394-000
Triumeq	Dolutegravir / abacavir / lamivudine	cdr_SR0387_Triumeq.pdf cdr_complete_SR0387_Triumeq_Apr-21-15.pdf SR0387_Triumeq_FDC_Review_Report_e.pdf	HIV Infection	List with criteria/condition	Complete	Jul 31, 2014	Apr 17, 2015	SR0387-000
Zaxine	Rifaximin	cdr_SR0388_Zaxine.pdf cdr_complete_SR0388_Zaxine-Apr-20-15.pdf SR0388_Zaxine_CL_Report_e.pdf SR0388_Zaxine_PE_Report_e.pdf SR0388 Zaxine_PI_Submissions_e.pdf	Hepatic encephalopathy	List with criteria/condition	Complete	Aug 5, 2014	Apr 16, 2015	SR0388-000
Aptiom	Eslicarbazepine acetate	cdr_SR0391_Aptiom.pdf cdr_complete_SR0391_Aptiom_Apr-20-15.pdf SR0391_Aptiom_CL_Report.pdf SR0391_Aptiom_PE_Report.pdf SR0391 Aptiom_PI_Submissions_e.pdf	Epilepsy, partial-onset seizures	List with criteria/condition	Complete	Aug 15, 2014	Apr 16, 2015	SR0391-000
Afinitor	Everolimus	cdr_SR0376_Afinitor_SEGA.pdf cdr_compelte_SR0376_Afinitor_Apr-17-15.pdf SR0376 Afinitor SEGA_Template_PI_Submissions.pdf SR0376_AfinitorSEGA_CL_Report_e.pdf SR0376_AfinitorSEGA_PE_Report.pdf	Subependymal giant cell astrocytoma associated with tuberous sclerosis complex	Do not list	Complete	Mar 19, 2014	Apr 15, 2015	SR0376-000
Esbriet	Pirfenidone	cdr_SR0393_Esbriet.pdf cdr_compelte_SR0393_Esbriet_Apr-17-15.pdf SR0393_Esbriet_CL_Report_resub.pdf SR0393_Esbriet_PE_Report_resub.pdf	Idiopathic pulmonary fibrosis	List with criteria/condition	Complete	Aug 29, 2014	Apr 15, 2015	SR0393-000
Vimizim	Elosulfase alfa	cdr_SR0389_Vimizim.pdf SR0389_complete_Vimizim_Mar-27-15.pdf SR0389_Vimizim_CL_Report_e.pdf SR0389_Vimizim_PE_Report_e.pdf SR0389 Vimizim_PI_Submissions_e.pdf	Mucopolysaccharidosis IVA (Morquio A syndrome)	Do not list	Complete	Aug 5, 2014	Mar 25, 2015	SR0389-000
Avastin	Bevacizumab	pcodr_provfund_avastin-cc.pdf pcodr-avastincc-fn-rec.pdf pcodr-avastin-cc-fn-cgr.pdf pcodr-avastin-cc-fn-egr.pdf pcodr-avastin-cc-in-rec.pdf pcodr-avastincc-pagfdk.pdf pcodr-avastincc-fdk-hlr.pdf pcodr-avastincc-fdk-occ.pdf pcodr-avastincc-coi-occ.pdf	Cervical Cancer	Reimburse with clinical criteria and/or conditions	Complete	Oct 27, 2014	Mar 23, 2015	PC0045-000
Revolade	Eltrombopag	cdr_SR0377_Revolade.pdf cdr_complete_SR0377_Revolade_Mar-23-2015_e.pdf SR0377_RevoladeTCP_CL_Report.pdf SR0377_RevoladeTCP_PE_Report.pdf SR0377 Revolade TCP_PI_Submissions.pdf	Thrombocytopenia associated with chronic hepatitis c infection	List with criteria/condition	Complete	Mar 31, 2014	Mar 18, 2015	SR0377-000
Prezcobix	Darunavir/cobicistat	cdr_SR0381_Prezcobix.pdf cdr_complete_ SR0381_Prezcobix_Mar_20-15.pdf SR0381_Prezcobix_CL_Report_e.pdf SR0381_Prezcobix_PE_Report_e.pdf media:document:3ceeb6a7-4e2b-4c15-ae53-9bec3bf123c4	HIV Infection	List with criteria/condition	Complete	May 22, 2014	Mar 18, 2015	SR0381-000
Harvoni	Ledipasvir / Sofosbuvir	cdr_SR0395_Harvoni.pdf cdr_complete_SR0395_Harvoni_Mar_20-15.pdf SR0395_Harvoni_CL_Report_e.pdf SR0395_Harvoni_PE_Report_e.pdf SR0395 Harvoni_PI_Submissions_e.pdf	Hepatitis C, chronic	List with criteria/condition	Complete	Sep 15, 2014	Mar 18, 2015	SR0395-000
Imbruvica	Ibrutinib	pcodr-provfund_ibrutinib_imbruvica-CLL.pdf pcodr-ibrutinib-cll-sll-fn-rec.pdf pcodr-ibrutinib-cll-sll-fn-cgr.pdf pcodr-ibrutinib-cll-sll-fn-egr.pdf pcodr-ibrutinib-cll-sll-in-rec.pdf pcodr-ibrutinib-pagfdk.pdf pcodr-ibrutinib-fdk-janssen.pdf pcodr-ibrutinib-fdk-llsccllpag.pdf pcodr-ibrutinib-coi-llsc.pdf pcodr-ibrutinib-coi-cllpag.pdf pcodr-ibrutinib-cll-sll-fdk-lc.pdf pcodr-ibrutinib-cll-sll-coi-lc.pdf	Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma	Reimburse with clinical criteria and/or conditions	Complete	Aug 15, 2014	Mar 5, 2015	PC0043-000
Signifor	Pasireotide diaspartate	cdr_SR0372_Signifor.pdf cdr_complete_SR0372_Signifor_Feb-26-15.pdf SR0372_Signifor_CL_Report.pdf SR0372_Signifor_PE_Report.pdf SR0372 Signifor_PI_Submissions.pdf	Cushing’s disease	Do not list	Complete	Feb 27, 2014	Feb 24, 2015	SR0372-000
Lucentis	Ranibizumab	cdr_SR0373_Lucentis.pdf cdr_complete_SR0373_Lucentis_CNV_Feb-20-15.pdf SR0373_LucentisCNV_CL_Report_e.pdf SR0373_LucentisCNV_PE_Report_e.pdf SR0373_Lucentis_PI_Submissions_e.pdf	Myopic choroidal neovascularisation	List with criteria/condition	Complete	Feb 28, 2014	Feb 19, 2015	SR0373-000
Actemra	Tocilizumab	cdr_SR0374_Actemra SC.pdf cdr_complete_SR0374_Actemra_SC_Feb-23-15.pdf SR0374_ActemraSC_CL_Report.pdf SR0374_ActemraSC_PE_Report.pdf SR0374_Actemra SC_PI_Submissions.pdf	Arthritis, rheumatoid	List with criteria/condition	Complete	Mar 3, 2014	Feb 19, 2015	SR0374-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 576 - 589 of 589

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 111 of 111

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 40 of 40

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 651 - 675 of 2093

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Wait List Strategies for CT and MRI	Wait List Strategies for CT and MRI	Jan 31, 2023	Health Technology Review	Technology Review	Completed	CM0002-000 - HC0052-000
maribavir	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Jan 26, 2023	Reimbursement Review		Complete	SR0720-000
abrocitinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder Feedback on Draft Recommendation	Jan 26, 2023	Reimbursement Review		Complete	SR0686-000
cabozantinib	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Jan 26, 2023	Reimbursement Review		Complete	PC0287-000
trastuzumab deruxtecan	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Jan 26, 2023	Reimbursement Review		Complete	PC0285-000
CADTH Pharmaceutical Reviews Update — Issue 33		Jan 26, 2023	Reimbursement Review	Pharmaceutical Review Update
empagliflozin	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Jan 24, 2023	Reimbursement Review		Complete	SR0726-000
Drug Safety and Effectiveness Data Access	Report - Drug Safety and Effectiveness Data Access	Jan 20, 2023	Health Technology Review	Technology Review	Completed	HC0029-000
pembrolizumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Jan 20, 2023	Reimbursement Review		Complete	PC0273-000
Olaparib (Lynparza) for metastatic castration-resistant prostate cancer - Details	10223OlaparibmCRPC_fnRec_REDACT_EC21Apr2021_final.pdf 10223OlaparibmCRPC_fnEGR_NOREDACT-ABBREV_EC21Apr2021_final.pdf 10223OlaparibmCRPC_fnCGR_REDACT_EC21Apr2021_final.pdf 10223OlaparibmCRPC_inRec_approvedbyChair_REDACT_Post01Apr2021_final.pdf 10223OlaparibmCRPC_PAGFeedback_EC21Apr2021_final_Redacted.pdf 10223OlaparibmCRPC_SponsorFeedback_EC21Apr2021_final.pdf 10223OlaparibmCRPC_ClinicianFeedback_EC21Apr2021_final.pdf 10223OlaparibmCRPC_Patient COI_CCSN_EC21Apr2021_final.pdf 10223OlaparibmCRPC_Combined Clinician COI_EC21Apr2021_final_Redacted.pdf	Jan 20, 2023	Reimbursement Review		Complete	PC0223-000
RET fusion-positive non-small cell lung cancer		Jan 18, 2023	Reimbursement Review	Provisional Funding Algorithm	Withdrawn	PH0020-000
ruxolitinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Jan 18, 2023	Reimbursement Review		Complete	SR0688-000
HER2-Positive Metastatic Breast Cancer	Final Report	Jan 16, 2023	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0006-000
Post‒COVID-19 Condition: A Condition-Level Review	Post-COVID 19 Condition (Long COVID) Scoping Summary	Jan 15, 2023	Health Technology Review	Condition Level Review	Completed	HL0001-000
Identifying Overused Lab Tests in Hospital Settings: A Delphi Study	Identifying Overused Lab Tests in Hospital Settings: A Delphi Study	Jan 13, 2023	Health Technology Review	Environmental Scan	Completed	ES0362-000
HER2 Positive Metastatic Breast Cancer	HER2 Positive Metastatic Breast Cancer - Final Report	Jan 13, 2023	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0016-000
faricimab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Jan 13, 2023	Reimbursement Review		Complete	SR0729-000
Metastatic Urothelial Carcinoma	Final Report	Jan 11, 2023	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0017-000
Renal Cell Carcinoma	Final Report	Jan 11, 2023	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0019-000
Copper and Ceruloplasmin Tests for Children With Global Developmental Delay and Intellectual Disability	Copper and Ceruloplasmin Tests for Children With Global Developmental Delay and…	Jan 9, 2023	Health Technology Review	Rapid Review	Completed	RC1467-000
pralsetinib	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Jan 6, 2023	Reimbursement Review		Complete	PC0283-000
Community Supports for People with Tuberculosis	Community Supports for People with Tuberculosis	Jan 4, 2023	Health Technology Review	Technology Review	Completed	HC0051-000
nivolumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Jan 3, 2023	Reimbursement Review		Complete	PC0272-000
Transition from alteplase (tPA) to tenecteplase (TNK) for thrombolysis for acute ischemic stroke		Dec 23, 2022	Health Technology Review	Policy Insight	In Progress	CY0015-000
abemaciclib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Dec 23, 2022	Reimbursement Review		Complete	PC0282-000